Extended and continuous use of hormonal contraceptives to reduce menstruation

Women's Health

Volumn 2, Issue 5, 2006, Pages 705-716

  Wiegratz, Inka ^a   Kissler, Stefan ^a   Kuhl, Herbert ^a   Kaufmann, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Bleeding pattern; Contraceptive efficacy; Extended regimen; Long cycle treatment; Oral contraceptive; Suppression of menstruation

Indexed keywords

ANTIBIOTIC AGENT; BARBITURIC ACID DERIVATIVE; CONTRACEPTIVE AGENT; CYTOCHROME P450; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DIENOGEST PLUS ESTRADIOL VALERATE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LYNESTRENOL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GLUCOSE; GONADORELIN AGONIST; LIPID; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; RIFAMPICIN; TRIPHASIC CONTRACEPTIVE AGENT;

ARTICLE; BLEEDING TENDENCY; BREAKTHROUGH BLEEDING; CARDIOVASCULAR DISEASE; CHINA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSMENORRHEA; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE FERTILITY; HORMONAL CONTRACEPTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION; MENSTRUATION DISORDER; METABOLIC DISORDER; NETHERLANDS; OVARY POLYCYSTIC DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PREGNANCY; QUALITY OF LIFE; RACE DIFFERENCE; RISK ASSESSMENT; SOUTH AFRICA; SPOTTING; TREATMENT DURATION; UNITED KINGDOM; UTERUS MYOMA; WITHDRAWAL BLEEDING;

EID: 33749511628     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.5.705     Document Type: Article

References (57)

1. Thomas SL, Ellertson C: Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet 355, 922-924 (2000).
2. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ: Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol. 95, 261-266 (2000).
3. den Tonkelaar I, Oddens B: Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 59, 357-362 (1999).
4. Wiegratz I, Kuhl H: Long-cycle treatment with oral contraceptives. Drugs 64(21), 2447-2462 (2004).
5. Glasier AF, Smith KB, van der Spuy ZM et al.: Amenorrhoea associated with contraception: an international study on acceptability. Contraception 67, 1-8 (2003).
6. Estanislau do Amaral MC, Hardy E, Hebling EM, Faundes A: Menstruation and amenorrhea: opinion of Brazilian women. Contraception 72, 157-161 (2005).
7. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H: Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 69, 37-42 (2004).
8. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL: Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am. J. Obstet. Gynecol. 186, 1142-1149 (2002).
9. Sulak PJ, Buckley T, Kuehl TJ: Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives. Contraception 73, 41-45 (2006).
10. Cachrimanidou A-C, Hellberg D, Nilsson S, Wildenström U, Olsson S-E, Sikström B: Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 48, 205-216 (1993).
11. Cachrimanidou A-C, Hellberg D, Nilsson S, von Schoulz B, Crona N, Siegbahn A: Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 50, 153-165 (1994).
12. Kovacs GT, Rusden J, Evans A: A trimonthly regimen for oral contraceptives. Br. J. Fam. Plann. 19, 274-275 (1994).
13. Ruchhoft E, Elkind-Hirsch KE, Malinak R: Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist. Fertil. Steril. 66, 54-60 (1996).
14. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ: Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet. Gynecol. 89, 179-183 (1997).
15. Miller L, Notter KM: Menstrual reduction with extended use of oral contraceptive pills: randomized controlled trial. Obstet. Gynecol. 98, 771-778 (2001).
16. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG: Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil. Steril. 77, 52-61 (2002).
17. Kwiecin M, Edelman A, Nichols MD, Jensen JT: Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 67, 9-13 (2003).
18. Miller L, Hughes JP: Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet. Gynecol. 101, 653-661 (2003).
19. Anderson FD, Hait H: A multicenter, randomized study of an extended cycle oral contraceptive: the Seasonale-301 Study Group. Contraception 68, 89-96 (2003).
20. Machado RB, Fabrini P, Cruz AM, Maia E, da Cunha Bastos A: Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg). Contraception 70, 365-370 (2004).
21. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD: Efficacy and safety of a continuous-use regimen of levonorgestrel/ ethinyl estradiol: North American Phase 3 study results. Conjoint Annual Meeting ASRM & CFAS, Montreal, Canada, 15-19 October, (2005) (Abstract P-49).
22. Archer DF, Kovalevsky G, Ballagh S, Grubb GS: Effect on ovarian activity of a continuous-use regimen of oral levonorgestrel/ethinyl estradiol. Conjoint Annual Meeting ASRM & CFAS. Montreal, Canada, 15-19 October, 2005 (Abstract O-57) (2005).
23. Portman D, Anderson FD, Gibbons W: Long-term safety of an extended regimen oral contraceptive (Seasonale): a 2-year multicenter trial. Contraception 72, 238 (2005) (Abstract 31).
24. LaGuarrdia KD, Stewart F, Kaunitz AM, Westhoff CL: Comparison of bleeding/spotting profiles between an extended regimen and a cyclic regimen of transdermal norelgestromin/ethinyl estradiol during the first 56 days of treatment. Contraception 72, 230 (2005) (Abstract 5).
25. Anderson FD, Hait H, Jeng H et al.: Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 71, 55-59 (2005).
26. Miller L, Verhoeven CHL, Hout J: Extended regimens of the contraceptive vaginal ring. Obstet. Gynecol. 106(3), 473-482 (2005).
27. Foidart JM, Sulak PJ, Schellschmidt I, Zimmermann D: The Yasmin® extended regimen study group: the use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Cantraception 73(1), 34-40 (2006).
28. Anderson FD, Gibbons W, Portman D: Safety and efficacy of an extended regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 73, 229-234 (2006).
29. Birtch RL, Olatunbosun OA, Pierson RA: Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception 73, 235-243 (2006).
30. Edelman AB, Koontz SL, Nichols MD, Jensen JT: Continuous oral contraceptives - are bleeding patterns dependent on the hormone given? Obstet. Gynecol. 107, 657-665 (2006).
31. Rosenberg M, Waugh MS: Causes and consequences of oral contraceptive non-compliance. Am. J. Obstet. Gynecol. 180, S276-S279 (1999).
32. Allen L: Extended use of the oral contraceptive pill - is it an acceptable option for the adolescent? J. Pediatr. Adolesc. Gynecol. 18, 285-288 (2005).
33. Spona J, Elstein M, Feichtinger W et al.: Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54, 71-77 (1996).
34. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil. Steril. 72, 115-120 (1999).
35. Schlaff W, Lynch AM, Hughes HD et al.: Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am. J. Obstet. Gynecol. 190, 943-951 (2004).
36. Guillebaud J: The forgotten pill and the paramount importance of the pill-free week. Br. J. Fam. Plann. 12 (Suppl.), S35-S43 (1987).
37. Edelman AB, Gallo MF, Nichols MD, Jensen JT, Schulz KF, Grimes DA: Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum. Reprod. 21, 573-578 (2006).
38. Pierson RA, Birtch RL, Olatunbosun OA: Ovarian follicular dynamics during conventional versus continuous oral contraceptive use. Conjoint Annual Meeting ASRM & CFAS, Montreal, Canada, 15-19 October, 2005 (Abstract O-58) (2005).
39. Teichmann AT, Kluft C, Grubb G, Constantine G, Spielmann D: Comparative trial of continuous-use and 21-day cyclic levonorgestrel and ethinyl estradiol oral contraceptive. Obstet. Gynecol. 107(Suppl.) 125 (2006).
40. Jung-Hoffmann C, Kuhl H: Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism. Am. J. Obstet. Gynecol. 163, 2183-2197 (1990).
41. Back DJ, Orme ML: Pharmacokinetic drug interactions with oral contraceptives. Clin. Pharmacokinet. 18, 472-484 (1990).
42. Park BK, Kitteringham NR, Pirmohamed M, Tucker GT: Relevance of Induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br. J. Clin. Pharmacol. 41, 477-491 (1996).
43. Guillebaud J: Practical prescribing of the combined oral contraceptive pill. In: Contraception - Science and Practice. Fishie M, Guillebaud J (Eds), Butterworths, London, UK, 69-93 (1989)
44. Marshall LM, Spiegelman D, Goldman MB et al.: A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil. Steril. 70, 432-439 (1998).
45. Friedman AJ, Thomas PP: Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomymomas? Obstet. Gynecol. 85, 631-635 (1995).
46. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE: Controversies in endocrinology: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J. Clin. Endocrinol. Metab. 88, 1927-1932 (2003).
47. Rizk DE, Kumar RM: Congenital afibrinogenemia: treatment of excessive menstrual bleeding with continuous oral contraceptive. Am. J. Hematol. 52, 237-238 (1996).
48. Milman N, Clausen J, Byg KE: Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann. Hematol. 77, 13-19 (1998).
49. Chuong CJ, Brenner PF: Management of abnormal uterine bleeding. Am. J. Obstet. Gynecol. 175, 787-792 (1996).
50. Mattson RH. Rebar RW: Contraceptive methods for women with neurologic disorders. Am. J. Obstet. Gynecol. 168, 2027-2032 (1993).
51. Lichten EM, Lichten JB, Whitty A: The confirmation of a biochemical marker for women's migraine: the depo-estradiol challenge test. Headache 36, 367-371 (1996).
52. Stanford JL, Brinton LA, Berman ML et al.: Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int. J. Cancer 54, 243-248 (1993).
53. Deligdisch L: Effects of hormone therapy on endometrium. Mod. Pathol. 6, 94-106 (1993).
54. Farrow A, Hull MG, Northstone K, Taylor H, Ford WC, Golding J: Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception. Hum. Reprod. 10, 2754-2761 (2002).
55. Wiegratz I, Mittmann K, Dietrich H, Zimmermann T, Kuhl H: Fertility after discontinuation of treatment with an oral contraceptive containing 30 μg ethinylestradiol and 2 mg dienogest. Fertil. Steril. 85, 1812-1819(2006).
56. Jung-Hoffmann C, Kuhl H: Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. Contraception 42, 423-428 (1990).
57. Clarke AK, Miller SJ: The debate regarding continuous use of oral contraceptives. Ann. Pharmacotherapy 35, 1480-1484 (2001).